Literature DB >> 6148121

The third drug in hypertension.

A Breckenridge.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148121      PMCID: PMC1443384          DOI: 10.1136/bmj.289.6449.859

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  5 in total

1.  Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade.

Authors:  R Zacest; E Gilmore; J Koch-Weser
Journal:  N Engl J Med       Date:  1972-03-23       Impact factor: 91.245

2.  Prognosis of treated hypertension. Changes in life expectancy and causes of death between 1952 and 1967.

Authors:  A Breckenridge; C T Dollery; E H Parry
Journal:  Q J Med       Date:  1970-07

3.  Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: possible alternative drug therapies.

Authors:  R P Ames
Journal:  Am J Cardiol       Date:  1983-02-24       Impact factor: 2.778

4.  Hydrallazine in hypertension: is there a safe dose?

Authors:  R F Bing; G I Russell; H Thurston; J D Swales
Journal:  Br Med J       Date:  1980-08-02

5.  The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors:  H A Cameron; L E Ramsay
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-18
  5 in total
  1 in total

Review 1.  Calcium channel blocking agents and the heart.

Authors:  J Kenny
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.